Literature DB >> 19293258

Stem cells and the natural history of lung cancer: implications for lung cancer screening.

Rob J van Klaveren1, Susan C van't Westeinde, Bart-Jan de Hoop, Henk C Hoogsteden.   

Abstract

Lung cancer is not simply a single disease, but a collection of several phenotypically very diverse and regionally distinct neoplasias. Its natural history is complex and not yet fully understood. Stem cells and the complex interaction with the microenvironment of the tumor and the immune system play an important role in tumor progression and metastasizing capacity. This finding explains why lung cancer does not always follow the multistep carcinogenetic and exponential growth model and why small lesions do not always equate to early-stage disease. Despite the fact that volume doubling times are increasingly used as surrogate markers for the natural history of lung cancer and as estimates for the proportion of overdiagnosed cases, it is only a momentary impression. At baseline screening especially, screen-detected lung cancer cases are preferably detected when they are in the indolent phase of their growth curve (length-biased sampling), from which it can by no means be concluded that they may not progress or metastasize at a later stage. Because the natural history of lung cancer is only partly elucidated, conclusions on the impact of overdiagnosis in lung cancer screening are premature.

Entities:  

Mesh:

Year:  2009        PMID: 19293258     DOI: 10.1158/1078-0432.CCR-08-1920

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  Attenuation of lung cancer stem cell tumorigenesis and metastasis by cisplatin.

Authors:  Shenxu Wang; Sai Ma; Xiujuan Li; Zengfu Xue; Xiaotian Zhang; Weiwei Fan; Yongzhan Nie; Kaichun Wu; Xiaoyuan Chen; Feng Cao
Journal:  Exp Lung Res       Date:  2014-08-25       Impact factor: 2.459

Review 2.  Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.

Authors:  Zhuang Luo; Rong-Rong Wu; Liang Lv; Peng Li; Li-Yan Zhang; Qing-Lin Hao; Wei Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers.

Authors:  William D Hazelton; Gary Goodman; William N Rom; Melvyn Tockman; Mark Thornquist; Suresh Moolgavkar; Joel L Weissfeld; Ziding Feng
Journal:  Math Biosci       Date:  2012-06-15       Impact factor: 2.144

4.  Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer.

Authors:  Aik T Ooi; Vei Mah; Derek W Nickerson; Jennifer L Gilbert; Vi Luan Ha; Ahmed E Hegab; Steve Horvath; Mohammad Alavi; Erin L Maresh; David Chia; Adam C Gower; Marc E Lenburg; Avrum Spira; Luisa M Solis; Ignacio I Wistuba; Tonya C Walser; William D Wallace; Steven M Dubinett; Lee Goodglick; Brigitte N Gomperts
Journal:  Cancer Res       Date:  2010-08-15       Impact factor: 12.701

5.  Multi-window CT based Radiomic signatures in differentiating indolent versus aggressive lung cancers in the National Lung Screening Trial: a retrospective study.

Authors:  Hong Lu; Wei Mu; Yoganand Balagurunathan; Jin Qi; Mahmoud A Abdalah; Alberto L Garcia; Zhaoxiang Ye; Robert J Gillies; Matthew B Schabath
Journal:  Cancer Imaging       Date:  2019-06-28       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.